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Abstract (250 words) 31 
Objectives 32 
Methicillin-resistant Staphylococcus aureus(MRSA) has spread across countries and 33 
healthcare settings, with different ecological niches for different clones. It is crucial to 34 
understand the comparative epidemiology of MRSA clones between healthcare 35 
settings, and independent factors associated with colonization of specific clones.   36 
 37 
Methods 38 
We conducted annual cross-sectional surveillance studies in a network comprising an 39 
acute-care hospital and six closely-affiliated intermediate- and long-term care facilities  40 
in Singapore, in June-July, 2014-2016. 5,394 patients contributed 16,045 nasal, axillary 41 
and groin samples for culture and MRSA isolates for whole genome sequencing. 42 
Multivariable multilevel multinomial regression models were constructed to assess for 43 
independent factors associated with MRSA colonization.  44 
 45 
Results  46 
MRSA clonal complex(CC) 22 was more prevalent in the acute-care hospital(51.9%) 47 
and intermediate-care(54.9%) than long-term care(25.1%) facilities, with clones 48 
besides CC22 and CC45 being prevalent in intermediate- and long-term care 49 
facilities(41.0%) (P<0.001). Groin colonization with CC45 was 6 times that of nasal 50 
colonization(aOR 6.21, 95%CI 4.26-9.01). Prior MRSA carriage was associated with 51 
increased odds of current MRSA colonization in all settings, with a stronger association 52 
with CC22(aOR 6.45, 95%CI 3.85-10.87) than CC45(aOR 4.15, 95%CI 2.26-7.58). 53 
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 54 
Conclusions 55 
Colonization of MRSA clones differed between anatomic sites and across healthcare 56 
settings. With CC22 having a predilection for the nares and CC45 the groin, MRSA 57 
screening should include both sites. Prior MRSA carriage is a risk factor for colonization 58 
with predominant MRSA clones in the acute-care hospital and intermediate- and long-59 
term care facilities. Contact precautions for prior MRSA-carriers on admission to any 60 
healthcare facility could prevent intra- and inter-institutional MRSA transmission.   61 
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INTRODUCTION  62 
Methicillin-resistant Staphylococcus aureus (MRSA) has disseminated globally, 63 
with many countries reporting MRSA proportions among S. aureus of >20% to >80% 64 
[1]. Studies have demonstrated a continuous evolution of MRSA clones, with rapid 65 
exchanges and spread across different countries and settings [2].  66 
The first healthcare-associated MRSA (HA-MRSA) clone to emerge was that 67 
belonging to multilocus sequence type (ST) 250 (“archaic clone”) [2]. The archaic clone 68 
gradually disappeared in the 1980s and was replaced by new pandemic clones [2,3]. 69 
One successful lineage was ST239, which became prevalent in the United Kingdom, 70 
United States and Australia in 1970-1980, in Europe and South America in 1980–1990, 71 
and subsequently in Asia and the Middle East in 1990–2000 [4]. In recent years, ST22-72 
SCCmec IV (EMRSA-15) is the major European HA-MRSA clone [5,6].   73 
In Asia, the major successful HA-MRSA clones were ST239 [7], ST5 (New York-74 
Japan clone) [7], ST22 (UK-EMRSA-15) [5], and ST45 [8-10]. Between the late 1980s 75 
and 2000, virtually all HA-MRSA in Singapore were ST239 [5,11]. Around 2000, ST22 76 
was imported into Singapore and became the dominant HA-MRSA clone by 2010 [5, 77 
11-13].  Since 2010, ST45 has been increasing in prevalence [9].	Phylogenetic analyses 78 
have revealed interdependent evolution of clones across acute care hospitals (ACHs) 79 
[5, 12], and between interconnected acute, and intermediate- and long-term care 80 
facilities (ILTCFs) [14]. The greater diversity of MRSA clones in ILTCFs suggests that 81 
they could have stronger connectivity with the community compared with the ACH. 82 
Different ecological niches have been observed for different MRSA clones. In Australia, 83 
clonal complex (CC) 22 has been observed to be more highly associated with patients 84 
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from subacute hospitals and long-term care facilities than CC239 [15]. We therefore 85 
sought to understand the comparative epidemiology of MRSA clones between 86 
healthcare settings, and to assess for independent factors associated with the 87 
colonization of specific clones, in order to guide the design and implementation of 88 
MRSA preventive strategies.  89 
 90 
METHODS 91 
Study design and settings 92 
Annual cross-sectional surveillance studies were conducted in a 1,700-bed 93 
adult tertiary-care ACH and its six most closely-affiliated ILTCFs, over six weeks in June-94 
July, from 2014 to 2016. The ILTCs included 3 intermediate-care facilities (ITCFs) 95 
(ITCF1: 100-bed rehabilitation center, ITCF2: 116-bed community hospital, ITCF3:360-96 
bed community hospital), and 3 long-term care facilities (LTCFs) (LTCF1: 234-bed 97 
nursing home, LTCF2: 164-bed chronic sick unit, LTCF3: 236-bed nursing home). All 98 
inpatients and residents of the ILTCFs were included in the study, and 3,040 in-patients 99 
with >48 hours stay in the ACH were randomly selected to participate in the study.  100 
 101 
Bacterial isolates 102 
Separate nasal, axillary, and groin swabs were obtained from study 103 
participants from the various institutions sequentially over each of the six-week 104 
periods annually. This was to capture the contemporaneity of MRSA isolates from the 105 
interconnected healthcare facilities, as the mutation rate of one core single-106 
nucleotide polymorphism (SNP) for MRSA is estimated to be every six weeks [5, 16].  107 
MRSA was cultured from the swabs, and DNA extracted from the isolates, using 108 
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conventional methods and subject to whole genome sequencing following previously 109 
described protocols [14].  110 
 111 
Genomic sequencing  112 
Multi-locus sequence types were determined from sequence reads using 113 
SRST2 [17]. Illumina reads were mapped onto a relevant reference sequences using 114 
SSAHA v2.2.1 [11]. The reference genome sequences used were: TW20 (accession 115 
number FN433596) for CC239 isolates, HO 5096 0412 (accession number HE681097) 116 
genome for CC22 isolates, CA-347 (accession number CP006044) (PUBMED; 117 
23887918) for the CC45 isolates. 118 
 119 
Data access 120 
Short reads for all sequenced isolates have been submitted to the European 121 
Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena/) under study accession number 122 
PRJEB9390. Individual accession numbers of sequences and assemblies for all isolates 123 
are listed in Supplementary Table 1. 124 
 125 
Administrative, Epidemiological, and Clinical data 126 
Administrative data from all institutions were electronically extracted. All 127 
epidemiological and clinical data from the ACH and some from the ILTCFs were 128 
obtained from the electronic medical records. Where unavailable electronically, 129 
clinical data from the ILTCFs were manually extracted from paper-based medical 130 
records by trained research assistants in a standardized manner.  The complete set of 131 
variables collected is provided in Supplementary Table 2.  132 
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 133 
Data analysis 134 
The differences in characteristics between MRSA-colonized and non-colonized 135 
patients, and between colonized patients with different types, number, and 136 
combinations of MRSA clones were compared using the Chi-square test or the 137 
Wilcoxon rank-sum test where appropriate. We explored the relationships between 138 
the various patient characteristics and anatomic sites and colonization with MRSA 139 
clones CC22, CC45, and other CCs, using multilevel multinomial logistic regression 140 
models with random intercepts, using PROC GLIMMIX in SAS version 9.4 (SAS Institute 141 
Inc, NC). We included variables selected a priori based on literature review and 142 
considered several multivariable multilevel multinomial logistic regression models 143 
involving the nesting of samples within patients to assess for independent factors 144 
associated with MRSA colonization. Negative 2 log-likelihood (-2LL) and likelihood-145 
ratio tests were used to compare between models and to guide the final model 146 
selection (Supplementary Table 3).   147 
 148 
Ethics approval 149 
The study was approved by the Domain Specific Review Board of National Healthcare 150 
Group Singapore (DSRB e 2015/00369). Informed consent was provided by all 151 
cognitively intact participants or the legally authorized representatives (LARs) of 152 
cognitively impaired participants. A waiver of informed consent was granted for 153 
cognitively impaired participants from the ITCFs who had no LARs. 154 
 155 
RESULTS 156 
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Over the three years, 5,394 patients were screened for MRSA, contributing to 157 
a total of 16,045 samples (Figure 1). The participation rate at the ILTCFs was 75%. 158 
Patients from the ACH, ITCF, and LTCF were similar in age and ethnicity (Table 1). 159 
Patients in the ACH had a shorter length of stay but were sicker (Charlson’s 160 
Comorbidity Index >5 27.5%) than those in the ITCFs (11.7%) and LTCFs (12.8%).  161 
The prevalence of MRSA in ITCFs (36.6%) and LTCFs (22.2%) were significantly 162 
higher than in the ACH (12.6%) (p<0.001) (Table 1). Patients who were older, male, 163 
with more comorbidities, who had a percutaneous device, longer length of stay, 164 
stayed in a room with more beds, prior and longer duration of antibiotics use, prior 165 
MRSA carriage or wound, were more likely to be MRSA colonized (Table 2). Among 166 
MRSA-colonized patients, those colonized with MRSA in more than one anatomic site 167 
included patients who had prior antibiotic exposures (P=0.04) and known MRSA 168 
carriers (P<0.001). Prior MRSA-carriers were also more likely to be colonized with 169 
different MRSA clones (P=0.05).  170 
We sequenced 1,478 MRSA isolates from the nares (585), axillae (178), and 171 
groin (715). The predominant lineages were CC22 (n=692, 46.8%) and CC45 (n=494, 172 
33.4%). CC22 was more prevalent in the ACH (51.9%) and ITCFs (54.9%) than LTCFs 173 
(25.1%) (P<0.001) (Figure 1). In contrast, LTCFs had the highest proportion (41.0%) of 174 
MRSA clones other than CC22 and CC45 (P<0.001). The distribution of MRSA clones in 175 
the ACH and ITCFs were similar throughout the three years, with CC22 and CC45 176 
remaining the predominant clones in 2016.  In the LTCFs, clones other than CC22 and 177 
CC45 predominated until 2016. CC22 was the most common clone colonizing the 178 
nares (54.4%), axillae (42.7%), and groin (41.7%), although CC45 had a stronger 179 
predilection for the groin (40.4%) than nares (26.2%) and axillae (29.2%) (P<0.001). In 180 
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patients who were colonized with more than one clone, 18 carried exclusively CC22 in 181 
the nares and CC45 in the groin. Only one patient carried more than one clone in the 182 
same anatomic site (nares, CC22 and CC8). 183 
After adjusting for age, gender, comorbidities, prior exposures to antibiotics 184 
and percutaneous devices, presence of wound, prior MRSA colonization, and year of 185 
screening, ITCF patients were more likely than ACH patients to be colonized with CC22 186 
(aOR 5.10, 95%CI 2.93-8.93) and CC45 (aOR 4.00, 95%CI 2.02-7.87), whilst LTCF 187 
patients were most likely to be colonized with other clones (aOR 4.24, 95%CI 1.44-188 
12.50) (Table 3). Nares were >9 times as likely as axillae to be colonized with all clones. 189 
Groin colonization odds with CC45 was 6 times that of nasal colonization, although it 190 
was not different with CC22 and other CCs. 191 
Stratified analysis by healthcare facility type further revealed that in ACH 192 
patients, the odds of colonization with MRSA clones other than CC45 in the nares was 193 
2-3 times that in the groin (Table 3). For all clones, the nares was 16-100 times more 194 
colonized than the axillae. In ILTCFs, patients were more likely to be colonized on the 195 
groin than nares for MRSA clones other than CC22. Prior MRSA carriage was strongly 196 
associated with MRSA colonization in ACH patients with CC22 (aOR 14.71, 95%CI 6.17-197 
34.48), CC45 (aOR 7.75, 95%CI 2.70-22.22) and other CCs (aOR 22.22, 95%CI 3.83-198 
125.00), but less so in the ILTCF patients. Additionally, a length of stay of >14 days was 199 
significantly associated with colonization with CC22 (aOR 2.67, 95%CI 1.22-5.88) in the 200 
ACH but not in ILTCFs. In ILTCF patients, prior exposure to any percutaneous device 201 
was associated with CC22 colonization (aOR 2.70, 95%CI 1.19-6.17).  202 
Almost one-in-five (18.4%) of the patients had prior MRSA carriage. Among 203 
non-prior MRSA carriers, the odds of MRSA colonization on the groin for all clones was 204 
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higher than in the nares (Table 4). In contrast, prior MRSA carriers were more likely to 205 
be colonized in the nares with all clones except CC45. Nineteen individuals were 206 
colonized with the same clones and in the same anatomic sites over 2-3 years. 207 
 208 
DISCUSSION 209 
We made contemporaneous comparisons of the epidemiology of MRSA clones 210 
within an interconnected healthcare network of an ACH and its closely-affiliated ITCFs 211 
and LTCFs, for three consecutive years. Ecological differences in MRSA clones were 212 
observed between facility types. Whilst CC22 and CC45 predominated in the ACH and 213 
ITCFs, other CCs circulated more in LTCFs. Similar findings on differing ecological 214 
niches of MRSA clones have been reported in Australia, where CC22 was associated 215 
with LTCF patients and CC239 with nosocomial acquisition in a tertiary hospital [15].  216 
 217 
Regardless of lineage, prior MRSA carriage in the preceding 12 months was 218 
associated with increased odds of current MRSA colonization in both the ACH and 219 
ILTCFs. The association was stronger with CC22 than CC45. This is to be expected as 220 
CC22 has been circulating in Singapore a decade before CC45 [9]. Of interest, the 221 
difference in effect sizes was most marked in patients from the ACH, with prior MRSA 222 
carriers being almost twice as likely to be colonized with CC22 than CC45. Whilst the 223 
relationship between prior MRSA carriage and MRSA colonization in ACHs has been 224 
well described in the literature [18], the associations between prior carriage and 225 
colonization of specific MRSA clones have not been previously reported. A history of 226 
MRSA positivity has been reported to increase the odds of MRSA carriage by almost 227 
seven times among patients newly admitted to rehabilitation centres in four European 228 
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countries [19]. Known current MRSA carriage also independently tripled the odds of 229 
MRSA colonization in nursing home residents [20].  230 
A length of stay >14 days was independently associated with the increased 231 
odds of colonization with CC22 in the ACH, but not in the ILTCFs. This suggests 232 
potential reservoirs of CC22 in the ACH resulting in colonization. A long acute-care 233 
hospital stay was also observed to similarly double the odds of MRSA carriage in 234 
patients on admission to rehabilitation centres [19]. The association between the 235 
increased length of stay in acute hospitals and MRSA acquisition has been previously 236 
reported [21]. However, the association with a particular clone of MRSA has yet to be 237 
reported. In patients from ILTCFs, prior exposure to percutaneous devices was 238 
associated with an increased odds of colonization with CC22, but not CC45 and other 239 
CCs. This suggests that the colonization could have occurred in the ACH, where the 240 
percutaneous devices were inserted.  241 
Nares are the most commonly used anatomic site for MRSA screening.  We 242 
observed that the nares of ACH patients were twice as likely as the groin to be 243 
colonized with CC22, but 6.5 times less likely to be colonized with CC45. Among ILTCF 244 
patients, the nares were similarly 6 times less likely than the groin to be colonized with 245 
CC45. Additionally, CCs other than CC22 and CC45 were almost thrice as likely to be 246 
colonized on the groin as in the nares. Among non-prior MRSA carriers, MRSA 247 
colonization on the groin for all clones was 1.8-10.9 times as high as that in the nares. 248 
As such, MRSA screening from nasal-only samples might miss detecting MRSA clones 249 
that have a predilection for the groin such as CC45 which is common in ACHs and ITCFs, 250 
and in non-prior MRSA carriers. In another study among HIV-infected individuals in 251 
Singapore, ST45 was observed to be >24 times more likely to be associated with 252 
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perianal colonization than in nares, axillae, and groin combined [22].  The predilection 253 
for the groin has also been observed for highly transmissible strains ST36 [23] and 254 
ST228 [24].  A handful of CC45 strains has been observed to harbor the Arginine 255 
Catabolic Mobile Element (ACME) [25], which has been suggested to enhance MRSA 256 
survival on the skin. Furthermore, a high proportion of CC45 isolates has been found 257 
to be non-susceptible to antibiotics including ciprofloxacin [26]. With the growing 258 
clinical and infection control importance of CC45, MRSA screening strategies would 259 
need to include groin swabs, in addition to nasal swabs. MRSA detection by culture 260 
and rapid PCR test has been found to increase from 48% and 62% respectively from 261 
nasal swabs alone to 79% and 92% with the addition of groin swabs [27].    262 
We observed that MRSA prevalence in ITCFs (36.6%) and LTCFs (22.2%) were 263 
thrice and twice that of the ACH (12.6%) respectively. The prevalence of MRSA in an 264 
Italian LTCF (14.8%) was similarly found to be twice that of the adjacent ACH’s geriatric 265 
unit (6.0%) [28], although MRSA prevalence in rehabilitation centres were reportedly 266 
similar to ACHs in several European countries (Germany, France, Spain, Italy) [29]. Our 267 
contemporaneous comparison of MRSA prevalence across healthcare facility types 268 
highlighted the importance of infection prevention measures in ITCFs and LTCFs. 269 
Whilst active MRSA screening at-admission and isolation or cohorting is routinely 270 
implemented in many ACHs, the care delivery models in ITCFs and LTCFs where 271 
patients/residents are encouraged to ambulate and socialize would not allow for 272 
isolation and segregation between MRSA-colonized and non-colonized 273 
patients/residents. Other strategies such as antiseptic bathing and intranasal 274 
antiseptics with close monitoring of antiseptic susceptibilities could be explored in 275 
ITCFs and LTCFs to reduce MRSA transmission [30].      276 
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 Our study was limited by the cross-sectional design. We acknowledge that only 277 
associational relationships can be derived from the study’s findings. Nonetheless, they 278 
have provided important insights into risk factors for MRSA colonization in an 279 
interconnected healthcare network.  280 
Our study’s strengths include the ability to concurrently assess for the 281 
prevalence and epidemiology of MRSA and its specific clones across different care 282 
settings in a healthcare network, from the ACH to ITCFs and LTCFs, within the same 283 
year and across three consecutive years. Furthermore, the study was able to assess 284 
for the colonization of specific MRSA clones on various anatomic sites. To minimize 285 
ascertainment bias, standardized protocols were used for data extraction from clinical 286 
notes, sample collection, sample processing and testing, with further confirmation of 287 
colonies for MRSA using matrix-assisted laser desorption/ionization-time of flight 288 
(MALDI-TOF) mass spectrometry. The medical technologist performing the 289 
microbiologic evaluation was blinded to the patients’ demographical and clinical 290 
information, rendering any detection bias negligible. Additionally, the ascertainment 291 
of prior MRSA carriage was based on laboratory records dated prior to the study 292 
screening date, making a causal relationship highly plausible.  Any selection bias due 293 
to nonparticipation was highly unlikely, with the high participation rate of 80% in the 294 
ILTCFs.  295 
 In conclusion, we found that the colonization of MRSA clones differed between 296 
anatomic sites and across healthcare settings. Whilst CC22 was more likely to colonize 297 
the nares, CC45 has a predilection for the groin.  Considerations should be made to 298 
include both the nares and groin for MRSA screening. Prior MRSA carriage is a 299 
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common risk factor for colonization with the predominant MRSA clones in both the 300 
ACH and ILTCFs. Hospital stay >14 days and exposure to percutaneous devices were 301 
additional risk factors for CC22 colonization in the ACH and ILTCFs respectively. Pre-302 
emptive contact precautions for prior MRSA-carriers on admission to any healthcare 303 
facility and active screening for long-stayers in the ACH could prevent intra- and inter-304 
institutional MRSA transmission. 305 
  306 
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Table 1. Characteristics of patients by admitted healthcare facilities 
Characteristics ACH (n = 2,985) ITCFs (n = 1,252) LTCFs (n = 1,157) 
Age, years 
     Mean ± SD 
     Median (IQR) 
     Range 
 
70.83 ± 15.02 
74 (62 – 82) 
21 – 106 
 
70.81 ± 12.64 
73 (63 – 80) 
25 – 99 
 
70.30 ± 14.07 
72 (61 – 82) 
27 – 106 
Age >65 years 2,010 (67.3) 872 (69.7) 753 (65.1) 
Male 1,644 (55.1) 641 (51.2) 612 (52.9) 
Ethnicity 
     Chinese 
     Malay 
     Indian 
















Charlson’s Comorbidity Index – median (IQR) 3 (1 – 6) 3 (1 – 4) 2 (1 – 4) 
Charlson’s Comorbidity Index >5 821 (27.5) 147 (11.7) 148 (12.8) 
Length of stay >14 days 972 (32.6) 856 (68.4) 1,157 (100.0) 
No. of beds per room of admitted facility 
     1 bed 
     2 – 4 beds 
     5 – 8 beds 
















Year of screening 
     2014 
     2015 













MRSA period prevalence 
     Overall 
     2014 
     2015 
















Values are expressed in number (%) unless indicated otherwise. 
Abbreviations: ACH, acute-care hospital; ITCFs, intermediate-term care facilities; IQR, interquartile range; LTCFs, long-term care facilities; SD, standard deviation.  
Table 2. Characteristics of patients by status of MRSA colonization 
Characteristics 
Non-colonized 
(n = 4,304) 
Total MRSA-colonized patients (n = 1,090) 
Colonized 
(n = 1,090) P1 
Single site 
(n = 764) 
Total multiple-site colonized patients (n = 326) 
Multiple sites 
(n = 326) P2 
Same clones 
(n = 261) 
Different clones 
(n = 65) P3 
Demographics          
Age, years 
     Mean ± SD 
     Median (IQR) 
     Range 
 
70.4 ± 14.5 
73 (62 - 81) 
21 - 106 
 
71.7 ± 13.4 
74 (63 - 82) 





71.3 ± 13.4 
73 (62 - 81) 
21 - 102 
 
72.8 ± 13.5 
75 (64 - 83) 





72.7 ± 13.4 
75 (64 - 83) 
29 - 99 
 
73.4 ± 13.8 
76 (67 - 85) 





Age > 65 years 2,873 (66.8) 762 (69.9) 0.05 525 (68.7) 237 (72.7) 0.19 188 (72.0) 49 (75.4) 0.59 
Male 2,196 (51.0) 701 (64.3) <0.001 491 (64.3) 210 (64.4) 0.96 165 (63.2) 45 (69.2) 0.37 
Ethnicity 
     Chinese 
     Malay 
     Indian 
































Admitted healthcare facility 
     ACH 
     ITCFs 


























Year of screening 
     2014 




















     2016 1,532 (35.6) 379 (34.8) 278 (36.4) 101 (31.0) 87 (33.3) 14 (21.5) 
Comorbidities          
CCI 
     Median (IQR) 
 
3 (1 - 5) 
 
3 (2 - 5) 
<0.001  
3 (1 - 5) 
 
3 (2 - 5) 
0.27  
3 (2 - 5) 
 
4 (2 - 6) 
0.22 
CCI > 5 875 (20.3) 241 (22.1) 0.19 167 (21.9) 74 (22.7) 0.76 56 (21.5) 18 (27.7) 0.28 
Cerebrovascular disease 1,554 (36.1) 477 (43.8) <0.001 336 (44.0) 141 (43.3) 0.83 114 (43.7) 27 (41.5) 0.76 
Congestive cardiac failure 529 (12.3) 148 (13.6) 0.25 99 (13.0) 49 (15.0) 0.36 39 (14.9) 10 (15.4) 0.93 
Chronic liver disease 289 (6.7) 75 (6.9) 0.85 49 (6.4) 26 (8.0) 0.35 18 (6.9) 8 (12.3) 0.15 
Chronic pulmonary disease 446 (10.4) 125 (11.5) 0.29 85 (11.1) 40 (12.3) 0.59 38 (14.6) 2 (3.1) 0.01 
Chronic renal disease 1,058 (24.6) 298 (27.3) 0.06 203 (26.6) 95 (29.1) 0.38 76 (29.1) 19 (29.2) 0.99 
Dementia 722 (16.8) 231 (21.2) <0.01 153 (20.0) 78 (23.9) 0.15 63 (24.1) 15 (23.1) 0.89 
Diabetes mellitus 1,775 (41.2) 495 (45.4) 0.01 343 (44.9) 152 (46.6) 0.60 115 (44.1) 37 (56.9) 0.06 
HIV infection 33 (0.8) 10 (0.9) 0.59 9 (1.2) 1 (0.3) 0.30c 1 (0.4) 0 (0.0) 1.00c 
Peptic ulcer disease 261 (6.1) 80 (7.3) 0.12 51 (6.7) 29 (8.9) 0.20 25 (9.6) 4 (6.2) 0.39 
Peripheral vascular disease 453 (10.5) 161 (14.8) <0.001 113 (14.8) 48 (14.7) 0.98 33 (12.6) 15 (23.1) 0.03 
 
Percutaneous devices 
         
Any a 3,492 (81.1) 922 (84.6) 0.01 637 (83.4) 285 (87.4) 0.09 225 (86.2) 60 (92.3) 0.18 
Arterial line 627 (14.6) 144 (13.2) 0.25 99 (13.0) 45 (13.8) 0.71 40 (15.3) 5 (7.7) 0.11 
Peripheral line 3,421 (79.5) 900 (82.6) 0.02 619 (81.0) 281 (86.2) 0.04 222 (85.1) 59 (90.8) 0.23 
PICC 175 (4.1) 70 (6.4) <0.01 46 (6.0) 24 (7.4) 0.41 17 (6.5) 7 (10.8) 0.29c 
Dialysis line 252 (5.9) 59 (5.4) 0.58 41 (5.4) 18 (5.5) 0.92 12 (4.6) 6 (9.2) 0.22c 
Endotracheal tube 523 (12.0) 134 (12.3) 0.78 83 (10.9) 51 (15.6) 0.03 44 (16.9) 7 (10.8) 0.23 
Nasogastric tube 1,210 (28.1) 426 (39.1) <0.001 293 (38.4) 133 (40.8) 0.45 109 (41.8) 24 (36.9) 0.48 
Chest tube 78 (1.8) 12 (1.1) 0.10 10 (1.3) 2 (0.6) 0.53† 2 (0.8) 0 (0.0) 1.00c 
PEG tube 362 (8.4) 152 (13.9) <0.001 106 (13.9) 46 (14.1) 0.92 34 (13.0) 12 (18.5) 0.26 
Suprapubic catheter 33 (0.8) 6 (0.6) 0.50 4 (0.5) 2 (0.6) 1.00† 2 (0.8) 0 (0.0) 1.00c 
Indwelling urinary catheter 1,217 (28.3) 432 (39.6) <0.001 304 (39.8) 128 (39.3) 0.87 101 (38.7) 27 (41.5) 0.68 
Tracheostomy 247 (5.7) 63 (5.8) 0.96 43 (5.6) 20 (6.1) 0.74 17 (6.5) 3 (4.6) 0.78 
Colostomy 54 (1.3) 18 (1.7) 0.31 11 (1.4) 7 (2.2) 0.40 7 (2.7) 0 (0.0) 0.35c 
Other factors          
Length of stay, days 
     Median (IQR) 
 
15 (7 - 57) 
 
32 (15 - 107) 
<0.001  
32 (15 - 112.5) 
 
31 (16 - 85) 
0.86  
31 (16 - 76) 
 
34 (17 - 115) 
0.55 
Length of stay >14 days 2,153 (50.0) 832 (76.3) <0.001 576 (75.4) 256 (78.5) 0.27 201 (77.0) 55 (84.6) 0.18 
No. of beds per room 
     1 bed 
     2 – 4 beds 
     5 – 8 beds 
































Prior antibiotics use b 3,214 (74.7) 912 (83.7) <0.001 628 (82.2) 284 (87.1) 0.04 224 (85.8) 60 (92.3) 0.31c 
Prior antibiotics use by days b 
     None 
     1 – 3 days 
     4 – 7 days 
     >7 days 






































Prior MRSA carriage 534 (12.4) 460 (42.2) <0.001 295 (38.6) 165 (50.6) <0.001 125 (47.9) 40 (61.5) 0.05 
Presence of wound 1,647 (38.3) 649 (59.5) <0.001 443 (58.0) 206 (63.2) 0.11 164 (62.8) 42 (64.6) 0.79 
Values are expressed in number (%) unless indicated otherwise. 
Single site colonization was defined as detection of an MRSA clone from one of three screening swabs (nares, axillae and groin swabs). 
Multiple sites colonization was defined as detection of MRSA clone in a minimum of two out of three screening swabs (nares, axillae and groin swabs). 
Multiple sites colonization was further categorized into same strain where same clone was cultured from body sites of each patient, and different strains otherwise. 
a Any percutaneous devices included procedures such as tracheostomy or colostomy, or insertion of any of the following: arterial line, dialysis line, peripherally-inserted central catheter, endotracheal tube, chest tube, 
PEG tube or suprapubic catheter in the preceding 12 months. 
b Prior antibiotics use included the use of any antibiotics comprising aminoglycoside, carbapenem, cephalosporin, fluoroquinolone, penicillin, or vancomycin in the preceding 12 months. 
c Fisher’s exact test 
Abbreviations: ACH, acute care hospital; CCI, Charlson’s comorbidity’s index; ITCFs, intermediate-term care facilities; IQR, interquartile range; LTCFs, long-term care facilities; MRSA, methicillin-resistant 
Staphylococcus aureus; PEG, percutaneous endoscopic gastrostomy; PICC, peripherally inserted central catheter; SD, standard deviation. 
P1; statistical test between MRSA-colonized and -non colonized patients 
P2; statistical test between single site and multiple sites colonized patients. 
P3; statistical test between same clones and different clones colonized patients. 
Table 3. Multilevel (16,045 samples nested within 5,394 patients) multivariable multinomial models of colonization with MRSA clones including CC22, CC45 and other CC with non-colonization as the reference 
category 
Variables Model 1 Model 2 Model 3 Model 4 Model 5 (final model) 





























































































Admitted healthcare facilities 





































































Year of screening 






























































Nares Reference Reference Reference Reference Reference 
Axilla 0.03 0.09 0.11 0.03 0.09  0.11 0.03 0.09  0.11 0.03 0.09 0.11 0.03 0.09 0.11 






















































































































































8982.01 8884.64 8875.00 8870.09 8851.77 
Likelihood 
ratio test P 
─ <0.001 <0.01 <0.05 <0.001 
 
  
Table 4. Stratified multilevel multivariable multinomial models of colonization with MRSA clones including CC22, CC45 and other CC with non-colonization as the reference category for the patients admitted to 
ACH (8,873 samples nested within 2,985 patients) and ILTCFs (7,172 samples nested within 2,409 patients) 
Variables ACH ILTCFs 
CC22 CC45 Other CC CC22 CC45 Other CC 
aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) 
Age >65 years 0.96 (0.41-2.25) 1.38 (0.45-4.20) 1.34 (0.29-6.29) 1.14 (0.61-2.10) 1.50 (0.74-3.06) 0.88 (0.36-2.18) 
Male 1.02 (0.46-2.27) 1.46 (0.51-4.17) 1.19 (0.30-4.76) 1.26 (0.70-2.26) 2.17 (1.11-4.26) 2.61 (0.98-6.94) 
Year of screening 
2014 Reference Reference 
2015 1.33 (0.50-3.57) 2.16 (0.69-6.76) 2.65 (0.50-13.89) 1.34 (0.65-2.75) 1.69 (0.76-3.75) 1.24 (0.41-3.76) 
2016 1.98 (0.77-5.10) 0.83 (0.22-3.09) 1.86 (0.32-10.64) 0.93 (0.44-1.97) 0.94 (0.40-2.21) 0.98 (0.32-3.03) 
Anatomic sites 
Nares Reference Reference 
Axilla 0.02 (0.01-0.03) 0.06 (0.02-0.15) 0.01 (0.002-0.04) 0.05 (0.03-0.08) 0.11 (0.06-0.18) 0.25 (0.14-0.46) 
Groin 0.43 (0.27-0.69) 6.49 (3.27-12.82) 0.30 (0.13-0.69) 1.35 (0.96-1.89) 6.10 (3.89-9.52) 2.88 (1.69-4.93) 
Prior MRSA carriage 14.71 (6.17-34.48) 7.75 (2.70-22.22) 22.22 (3.83-125.00) 2.72 (1.35-5.46) 2.36 (1.06-5.24) 2.22 (0.76-6.45) 
CCI >5 1.01 (0.45-2.29) 0.97 (0.34-2.70) 0.94 (0.24-3.70) 1.17 (0.53-2.62) 1.10 (0.44-2.74) 0.77 (0.20-3.02) 
Prior percutaneous device use 1.31 (0.10-17.54) 0.74 (0.04-13.16) 0.69 (0.01-58.82) 2.70 (1.19-6.17) 1.38 (0.62-3.09) 0.64 (0.22-1.82) 
Presence of wounds 1.07 (0.47-2.46) 2.29 (0.77-6.85) 1.41 (0.32-6.10) 1.41 (0.77-2.61) 1.14 (0.57-2.28) 1.71 (0.64-4.52) 
Prior antibiotics use 1.12 (0.22-5.65) 1.05 (0.13-8.55) 1.57 (0.04-55.56) 1.64 (0.77-3.51) 1.31 (0.59-2.89) 2.34 (0.71-7.69) 
LOS > 14 days 2.67 (1.22-5.88) 2.69 (0.99-7.30) 1.57 (0.42-5.95) 1.16 (0.55-2.46) 1.69 (0.64-4.44) 2.30 (0.45-11.76) 
Abbreviations: ACH, acute care hospital; aOR; adjusted odds ratio; CCI, Charlson’s comorbidity index; CI; confidence interval; ILTCFs, intermediate- and long-term care facilities; LOS, length of stay 
  
Table 5. Stratified multilevel multivariable multinomial models of colonization with MRSA clones including CC22, CC45 and other CC with non-colonization as the reference category for the patients with (2,961 
samples nested within 994 patients) or without (13,084 samples nested within 4,400 patients) prior MRSA carriage 
Variables Prior MRSA carriage 
Yes No 
CC22 CC45 Other CC CC22 CC45 Other CC 
aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) 
Age >65 years 1.10 (0.56-2.18) 1.33 (0.54-3.30) 0.92 (0.29-2.87) 0.97 (0.50-1.91) 1.53 (0.70-3.34) 1.13 (0.40-3.23) 
Male 0.83 (0.44-1.57) 1.16 (0.50-2.71) 1.14 (0.37-3.50) 1.39 (0.73-2.64) 2.62 (1.24-5.56) 3.13 (1.04-9.43) 
Admitted healthcare facilities 
ACH Reference Reference 
ITCFs 3.24 (1.46-7.14) 2.92 (1.11-7.69) 1.15 (0.28-4.74) 8.13 (3.55-18.52) 5.95 (2.16-16.39) 4.85 (0.73-32.26) 
LTCFs 0.44 (0.16-1.22) 0.77 (0.20-2.91) 1.47 (0.31-6.94) 1.61 (0.52-4.95) 2.68 (0.81-8.93) 14.08 (1.94-100.00) 
Year of screening 
2014 Reference Reference 
2015 1.75 (0.83-3.70) 2.10 (0.81-5.43) 2.49 (0.66-9.26) 1.26 (0.57-2.79) 1.81 (0.76-4.35) 1.09 (0.31-3.85) 
2016 2.27 (1.07-4.81) 0.88 (0.31-2.45) 1.61 (0.40-6.45) 1.01 (0.45-2.26) 0.91 (0.35-2.36) 0.84 (0.23-3.06) 
Anatomic sites 
Nares Reference Reference 
Axilla 0.04 (0.02-0.10) 0.05 (0.02-0.10) 0.02 (0.01-0.06) 0.04 (0.02-0.07) 0.15 (0.09-0.28) 0.33 (0.17-0.64) 
Groin 0.46 (0.31-0.70) 2.65 (1.58-4.46) 0.51 (0.27-0.97) 1.81 (1.24-2.63) 10.87 (6.45-18.52) 3.24 (1.76-5.95) 
CCI >5 1.15 (0.60-2.21) 1.09 (0.46-2.60) 0.95 (0.30-2.99) 1.20 (0.50-2.87) 1.06 (0.38-2.90) 0.66 (0.13-3.36) 
Any percutaneous devices 3.37 (0.46-25.00) 2.56 (0.20-32.26) 1.22 (0.05-30.30) 1.47 (0.54-3.98) 0.92 (0.35-2.44) 0.89 (0.26-3.03) 
Presence of wounds 0.69 (0.36-1.34) 1.25 (0.52-3.02) 1.18 (0.36-3.79) 1.37 (0.70-2.68) 1.33 (0.62-2.85) 2.26 (0.75-6.85) 
Prior antibiotics use 3.94 (0.89-17.54) 1.14 (0.20-6.45) 2.51 (0.16-40.00) 1.35 (0.60-3.06) 1.23 (0.51-2.92) 2.13 (0.60-7.63) 
LOS >14 days 2.02 (1.04-3.94) 1.72 (0.71-4.17) 1.28 (0.39-4.26) 2.84 (1.27-6.37) 4.10 (1.38-12.20) 2.03 (0.30-14.08) 
Abbreviations: ACH, acute care hospital; aOR; adjusted odds ratio; CCI, Charlson’s comorbidity index; CI; confidence interval; ITCFs, intermediate-term care facilities; LOS, length of stay; LTCFs, long-term care 
facilities 
  



























Abbreviations: ACH, acute care hospital; CC, clonal complex; ITCFs, intermediate-term care facilities; LTCFs, long-term care facilities 
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